

1 **Sex influences the effects of APOE genotype and Alzheimer’s diagnosis on neuropathology**  
2 **and memory**

3 Paula Duarte-Guterman<sup>1#</sup>, Arianne Y. Albert<sup>2</sup>, Cindy K. Barha<sup>3</sup>, Liisa A.M. Galea<sup>1</sup>, on behalf of  
4 the Alzheimer’s Disease Neuroimaging Initiative<sup>δ</sup>

5  
6 <sup>1</sup>. Djavad Mowafaghian Centre for Brain Health and Department of Psychology, University of  
7 British Columbia, Vancouver, BC, Canada

8 <sup>2</sup>. Women's Health Research Institute of British Columbia, Vancouver, BC, Canada

9 <sup>3</sup>. Djavad Mowafaghian Centre for Brain Health and Department of Physical Therapy, University  
10 of British Columbia, Vancouver, BC, Canada

11  
12 Address all correspondence and requests for reprints to:

13 L. A. M. Galea, PhD  
14 Djavad Mowafaghian Centre for Brain Health  
15 2215 Wesbrook Mall  
16 Vancouver, British Columbia  
17 V6T 1Z3, Canada  
18 E-mail: [liisa.galea@ubc.ca](mailto:liisa.galea@ubc.ca)

19  
20  
21 # Present Address: Department of Psychology, Brock University, St. Catharines, ON, Canada

22  
23 <sup>δ</sup> Data used in preparation of this article were obtained from the Alzheimer’s Disease  
24 Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). As such, the investigators within  
25 the ADNI contributed to the design and implementation of ADNI and/or provided data but did  
26 not participate in analysis or writing of this report. A complete listing of ADNI investigators can  
27 be found at: [http://adni.loni.usc.edu/wp-](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)  
28 [content/uploads/how\\_to\\_apply/ADNI\\_Acknowledgement\\_List.pdf](http://adni.loni.usc.edu/wp-content/uploads/how_to_apply/ADNI_Acknowledgement_List.pdf)

29  
30  
31  
32 **Keywords:** mild cognitive impairment; tau, amyloid beta; hippocampus; executive function;  
33  
34 gender.

35 **Abstract**

36 Alzheimer's disease (AD) is characterised by severe cognitive decline and pathological  
37 changes in the brain (brain atrophy, hyperphosphorylation of tau, and deposition of toxic  
38 amyloid-beta protein). Females have greater neuropathology (AD biomarkers and brain atrophy  
39 rates) and cognitive decline than males, however these effects can depend on diagnosis (amnesic  
40 mild cognitive impairment (aMCI) or AD) and APOE genotype (presence of  $\epsilon 4$  alleles). Using  
41 the ADNI database (N=630 females, N=830 males), we analysed the effect of sex, APOE  
42 genotype (non-carriers or carriers of APOE $\epsilon 4$  alleles), and diagnosis (cognitively normal (CN),  
43 early aMCI (EMCI), late aMCI (LMCI), probable AD) on cognition (memory and executive  
44 function), hippocampal volume, and AD biomarkers (CSF levels of amyloid beta, tau and ptau).  
45 Regardless of APOE genotype, memory scores were higher in CN, EMCI, and LMCI females  
46 compared to males but this sex difference was absent in probable AD, which may suggest a  
47 delay in the onset of cognitive decline or diagnosis and/or a faster trajectory of cognitive decline  
48 in females. We found that, regardless of diagnosis, CSF tau-pathology was disproportionately  
49 elevated in female carriers of APOE $\epsilon 4$  alleles compared to males. In contrast, male carriers of  
50 APOE $\epsilon 4$  alleles had reduced levels of CSF amyloid beta compared to females, irrespective of  
51 diagnosis. We also detected sex differences in hippocampal volume but the direction was  
52 dependent on the method of correction. Altogether results suggest that across diagnosis females  
53 show greater memory decline compared to males and APOE genotype affects AD  
54 neuropathology differently in males and females which may influence sex differences in  
55 incidence and progression of aMCI and AD.

## 56 **1. Introduction**

57 Alzheimer's disease (AD) is characterized by severe cognitive decline and  
58 neuropathological markers such as brain atrophy, hyperphosphorylation of tau, and deposition of  
59 toxic amyloid-beta ( $A\beta$ ) protein in the brain (Alzheimer's Association, 2017). The hippocampus  
60 is one of the first brain areas to show atrophy with AD (Jack et al., 2000; Kidron et al., 1997) and  
61 hippocampal atrophy correlates with cognitive decline (Petersen et al., 2000) and AD pathology  
62 (neurofibrillary tangles; Jack et al., 2002). Possession of one or two APOE $\epsilon$ 4 alleles, the  
63 strongest genetic risk factor for sporadic AD, and female sex are important non-modifiable risk  
64 factors for AD (Riedel et al., 2016). Studies indicate that females with AD show greater signs of  
65 neuropathology (tau levels), rates of brain atrophy, including in the hippocampus, and cognitive  
66 decline than males, which may be exacerbated by APOE genotype (e.g., Ardekani et al., 2016;  
67 Buckley et al., 2018; Cavedo et al., 2018; Hohman et al., 2018). One allele of APOE $\epsilon$ 4 increases  
68 the risk of AD in females relative to males between 65 and 75 years, indicating that the APOE  
69 genotype affects males and females differently (Neu et al., 2017).

70 Previous studies have examined the interaction of APOE genotype and sex on AD  
71 biomarkers (tau and  $A\beta$ ), hippocampal atrophy, and cognitive function, but findings are not  
72 consistent (Altmann et al., 2014; Buckley et al., 2018; Damoiseaux et al., 2012; Holland et al.,  
73 2013; Liu et al., 2019; Sampedro et al., 2015; Sohn et al., 2018; Wang et al., 2019), likely due to  
74 the diagnosis groups included and whether studies use longitudinal or baseline comparisons.  
75 Using the Alzheimer's Disease Neuroimaging Initiative (ADNI) database, previous studies found  
76 a stronger association between APOE $\epsilon$ 4 and CSF tau levels in females compared to males at  
77 baseline in cognitively normal (CN; Damoiseaux et al., 2012; but see Sampedro et al., 2015) and  
78 amnesic mild cognitive impairment (aMCI) individuals (Altmann et al., 2014; Liu et al., 2019)  
79 but no studies to our knowledge have investigated the interactions between sex and APOE

80 genotype in individuals with AD. Females with APOE $\epsilon$ 4 alleles have steeper hippocampal  
81 volume reductions with age in CN individuals (Holland et al., 2013) and show greater cognitive  
82 decline in aMCI individuals (Sohn et al., 2018; Wang et al., 2019) compared to males but these  
83 findings are not consistent (Buckley et al., 2018). Although there are several ADNI studies that  
84 have examined sex by APOE genotype interactions on AD biomarkers, most of these studies  
85 included only one diagnosis group, with either only CN (Buckley et al., 2018, 2019a) or aMCI  
86 groups (Liu et al., 2019; Sohn et al., 2018) or analysed the groups (CN, aMCI, AD) separately  
87 (Sundermann et al., 2018). It is important to include all three diagnosis groups CN, aMCI and  
88 AD to understand how sex may interact with APOE genotype to influence AD biomarkers across  
89 diagnosis. In order to improve diagnosis and treatment, it is important to understand why females  
90 are at a higher lifetime risk and have a higher burden of the disease than males and whether this  
91 is across diagnosis and APOE genotype for a number of AD biomarkers.

92 Sex differences in memory depend on memory domain, females perform better in  
93 episodic memory tasks related to verbal memory, whereas males perform better in visuospatial-  
94 related tasks (meta-analysis by Asperholm et al., 2019). Furthermore, there are sex differences in  
95 some forms of executive function depending on the type of executive function being examined,  
96 with a male advantage for working memory and a female advantage on response inhibition in  
97 cognitively healthy adults (Gaillard et al., 2020). In tasks that involve the integrity of the  
98 hippocampus, males typically outperform females in both humans and rodents (Yagi and Galea,  
99 2019). In addition, while sex differences in hippocampal volume have been detected, with  
100 females having a smaller volume compared to males, this depends on whether the data are  
101 corrected for individual differences in brain volume and the method of correction employed  
102 (meta-analysis by Tan et al., 2016). Understanding basic sex differences in hippocampal function

103 and structure is important to determine how they can contribute to sex differences in  
104 vulnerability and progression of neurodegenerative diseases in which the integrity of the  
105 hippocampus is affected such as in AD.

106 The objective of this study was to examine sex differences in AD biomarkers (CSF A $\beta$ ,  
107 tau, and phosphorylated tau), volume of the hippocampus (using two correction factors),  
108 memory, and executive function, and how these may be affected by APOE genotype (non-  
109 carriers or carriers of APOE $\epsilon$ 4 alleles) and diagnosis status (CN, aMCI, probable AD). We  
110 hypothesized that females will be more affected by APOE genotype and diagnosis and this will  
111 be reflected in greater AD pathology, smaller hippocampus volume, and lower cognitive scores  
112 than males with probable AD and this is exacerbated in female carriers of APOE $\epsilon$ 4 alleles.

113

## 114 **2. Materials and methods**

### 115 *2.1 ADNI database*

116 Data used in the preparation of this article were obtained from the Alzheimer's Disease  
117 Neuroimaging Initiative (ADNI) database ([adni.loni.usc.edu](http://adni.loni.usc.edu)). The ADNI was launched in  
118 2003 as a public-private partnership, led by Principal Investigator Michael W. Weiner,  
119 MD. The primary goal of ADNI has been to test whether serial magnetic resonance imaging  
120 (MRI), positron emission tomography (PET), other biological markers, and clinical and  
121 neuropsychological assessment can be combined to measure the progression of mild cognitive  
122 impairment (MCI) and early Alzheimer's disease (AD). For up-to-date information, see  
123 [www.adni-info.org](http://www.adni-info.org). Data used in this article were downloaded on or before Jan 16, 2019.  
124 Participants (between the ages of 55 and 90) were recruited across the United States and Canada  
125 and agreed to complete a variety of imaging and clinical assessments at baseline and repeated at  
126 specific intervals (Petersen et al., 2010). The study design and schedule is available online:

127 (<http://adni.loni.usc.edu/study-design/>). Inclusion and exclusion criteria are detailed online  
128 (<http://adni.loni.usc.edu/methods/documents/>). Briefly, CN participants had normal memory  
129 function (measured by education-adjusted scores on the Wechsler Memory Scale Logical  
130 Memory II) and a Clinical Dementia Rating (CDR) of 0. Amnestic late MCI (LMCI) participants  
131 had objective memory loss (from Wechsler Memory Scale Logical Memory II scores), a CDR of  
132 0.5, preserved daily activities, and absence of dementia. Early MCI (EMCI) participants had a  
133 milder episodic memory impairment compared to LMCI (Wechsler Memory Scale Logical  
134 Memory II scores  $\sim$ 0.5 and 1.5 SD below the mean of CN participants). Participants that met  
135 NINCDS/ADRDA Alzheimer's Criteria and a CDR of 0.5 or 1.0 were categorised as probable  
136 AD.

137

## 138 *2.2 CSF biomarkers, hippocampal volume, memory, and executive function*

139 We included all participants who had the following baseline data: diagnosis in the ADNI  
140 database, cerebrospinal fluid (CSF) levels for A $\beta$ , tau and phosphorylated tau (ptau), had a brain  
141 MRI scan, and underwent a battery of neuropsychological tests (total n = 1,460, n= 630 females,  
142 n=830 males; Table 1). Data included in our analyses were: demographics (age, years of  
143 education, and ethnicity), baseline diagnosis (cognitively normal, CN; EMCI; LMCI; or probable  
144 AD), number of APOE  $\epsilon$ 4 alleles (0, 1 or 2), CSF A $\beta$  (pg/ml), CSF tau (pg/ml), and CSF p-tau  
145 (pg/ml), hippocampal volume (mm<sup>3</sup>), ADNI executive function z-scores, and ADNI memory z-  
146 scores (using data from the ADNI neuropsychological battery and validated in Crane et al., 2012;  
147 Gibbons et al., 2012). The executive function score included WAIS-R Digit Symbol Substitution,  
148 Digit Span Backwards, Trails A and B, Category Fluency, and Clock Drawing (Gibbons et al.,  
149 2012). The composite memory score included Rey Auditory Verbal Learning Test, AD

150 Assessment Schedule - Cognition, Mini-Mental State Examination, and Logical Memory data  
151 (Crane et al., 2012). APOE genotype was determined from EDTA blood samples collected at  
152 baseline (for a detailed protocol see: Shaw et al., 2009). Tau and A $\beta$  levels were determined in  
153 CSF collected in the morning after an overnight fast and using the micro-bead-based multiplex  
154 immunoassay, the INNO-BIA AlzBio3 RUO test (Fujirebio, Ghent, Belgium) on the Luminex  
155 platform (for details see: Shaw et al., 2009). MRI scans were obtained according to standardised  
156 protocol (<http://adni.loni.usc.edu/methods/mri-analysis/mri-acquisition/>). Hippocampal volume  
157 data were analysed using FreeSurfer (<https://surfer.nmr.mgh.harvard.edu>) version 4.3 for ADNI  
158 1 and version 5.1 for ADNI GO and 2 at the University of California – San Francisco  
159 (<http://adni.loni.usc.edu/methods/>). Sex differences in hippocampal volume are influenced by  
160 controlling factors such as intracranial volume (Lotze et al., 2019; Tan et al., 2016). In the  
161 present study, we corrected hippocampus volume using two different methods. The first method  
162 (regression method) used the method in Mormino et al. (2014) and Jack et al. (2012) using the  
163 residuals of the linear regression between hippocampal volume and total intracranial volume. We  
164 also compared another widely used volume correction method (Sohn et al., 2018; Sundermann et  
165 al., 2018; meta-analysis by Tan et al., 2016) by dividing hippocampal volume with intracranial  
166 volume to directly compare the different correction methods.

167

### 168 *2.3 Statistical Methods*

169 We compared all available data for each study variable between the sexes using the  
170 Wilcoxon rank sum test for continuous variables and Fisher's exact test for categorical variables.  
171 We used general linear models to determine the relationships between sex, APOE genotype  
172 (non-carriers or carriers of APOE $\epsilon$ 4 alleles), and diagnosis status (CN, EMCI, LMCI, and

173 probable AD) as predictor variables, and AD biomarkers, corrected hippocampal volume, and  
174 cognitive ability, as dependent variables. All models included age and years of education as a  
175 covariate. All models initially included the three-way interaction between sex, APOE genotype,  
176 and diagnosis; if this interaction was not significant, it was removed from the model to estimate  
177 the two way interactions (sex and APOE genotype, sex and diagnosis, APOE genotype and  
178 diagnosis). If no two-way interactions were significant, these were removed from the model to  
179 estimate the main effects of sex, APOE genotype, and diagnosis. Significance was based on the  
180 likelihood ratio test, and all p-values were corrected for multiple testing using the Benjamini-  
181 Hochberg false discovery rate method with the family-wise error rate set to 0.05 (Benjamini and  
182 Hochberg, 1995). In total, seven p-values per dependent variable were included in each set of  
183 models (interaction terms and main effects of sex, APOE, and diagnosis) resulting in 49 p-values  
184 corrected (seven dependent variables; Tables 1 and 2). Significant interaction terms were  
185 followed up using pairwise simple-effects tests with Benjamini-Hochberg p-value correction. We  
186 calculated Pearson's correlation coefficients between CSF levels of tau and A $\beta$  by sex and APOE  
187 genotype separately. We report significance differences (adjusted  $p \leq 0.05$ ). All regression  
188 analyses were carried out in R v3.5.1 (R Core Team, 2018).

189

### 190 **3. Results**

#### 191 *3.1 Demographic information*

192 Table 1 gives a summary of the variables in the data set (N=1460). Overall, females were  
193 significantly younger and had fewer years of education than males ( $p$ 's<0.0001) and hence age  
194 and education were used as covariates in all analyses. There were more white males than white  
195 females in our sample and more non-white females compared to non-white males ( $p < 0.05$ ). In



196 terms of APOE genotype, there were no sex differences in distribution of APOE genotype with  
197 40% females and 38.8% males possessing one allele of APOE $\epsilon$ 4, and 11% females and 12% of  
198 males possessing two alleles of APOE $\epsilon$ 4. The proportion of participants in each of the diagnosis  
199 categories was significantly different for females and males ( $p < 0.05$ ). More females were  
200 cognitively normal than males (26.7% compared to 20.8%, unadjusted  $p = 0.01$ ) but there were no  
201 sex differences in baseline diagnosis of probable AD (females: 23.7% compared to males:  
202 21.7%, unadjusted  $p = 0.41$ ). However, there were more males with a diagnosis of LMCI (39.5%  
203 versus 32.5%, unadjusted  $p = 0.007$ ) but not EMCI (18.0% versus 17.1%, unadjusted  $p = 0.74$ )  
204 compared to females.

205 We tested whether sex, APOE genotype (non-carriers or carriers of APOE $\epsilon$ 4 alleles), and  
206 diagnosis status (CN, EMCI, LMCI, and probable AD) influenced cognitive ability, corrected  
207 hippocampal volume, and CSF biomarkers of AD in one model. However, we did not find  
208 significant interactions between these three factors in any of the models (i.e. none of the three-  
209 way interactions were significant). We did find significant two-way interactions between sex and  
210 APOE genotype, sex and diagnosis, and APOE genotype and diagnosis (Table 2) on these  
211 dependent variables, which are discussed in turn below.

212

### 213 *3.2. Sex and APOE genotype were associated with changes in CSF AD biomarkers*

214 We found significant interactions between sex and APOE genotype for CSF tau, and p-  
215 tau ( $p = 0.005$  and  $0.006$ , respectively), and a trend for CSF A $\beta$  ( $p = 0.051$ ; Table 2). Tau and p-tau  
216 levels were significantly higher in female carriers of APOE $\epsilon$ 4 alleles compared to male carriers  
217 (all  $p$ 's  $< 0.0001$ ; Fig. 1 A and B) but no sex differences were detected in non-carriers of APOE $\epsilon$ 4  
218 alleles ( $p > 0.3$ ). Although CSF tau and p-tau levels were also higher in males with APOE $\epsilon$ 4

219 genotype, the difference in levels between carriers and non-carriers was more pronounced in  
220 females (standardized regression coefficients for tau and ptau: 0.46 and 0.49 in females and 0.19  
221 and 0.24 in males). For CSF A $\beta$ , post-hoc comparisons showed that female APOE $\epsilon$ 4 carriers had  
222 higher levels compared to males carriers (p=0.04) but there were no sex differences in non-  
223 carriers (p=0.6; Fig. 1 C). Levels of CSF A $\beta$  were lower in both sexes in carriers of APOE $\epsilon$ 4  
224 alleles but the difference between carriers and non-carriers was more pronounced in males than  
225 in females, irrespective of diagnosis (standardized regression coefficients for A $\beta$ : -0.58 in  
226 females and -0.71 in males). There were no significant sex by diagnosis interactions for AD  
227 biomarkers (Table 2).

228 We next investigated the relationship, using correlations, between CSF tau and A $\beta$  levels  
229 in males and females and by APOE genotype (Table 3). We found significant negative  
230 correlations between CSF levels of tau and A $\beta$  in male and female non-carriers of APOE $\epsilon$ 4  
231 alleles (r=-0.262, p<0.0001; r=-0.195, p=0.008, respectively). However, in carriers of APOE $\epsilon$ 4  
232 alleles, a significant negative correlation was found only in females (r=-0.219, p=0.001) but not  
233 in males (r= -0.046, p=0.44).

234

### 235 *3.3. Sex and diagnosis were associated with changes in memory scores*

236 We found a significant interaction between sex and diagnosis for ADNI memory z-scores  
237 (p=0.048; Table 2). Females had significantly higher memory z-scores than males in the CN,  
238 EMCI, and LMCI groups (p<0.001, p<0.001, p<0.01, respectively) while no sex differences  
239 were detected in probable AD (p=0.1). Thus, severity of diagnosis decreased memory scores to a  
240 greater extent in females, such that there was no longer a sex differences in memory scores in  
241 individuals with AD (Fig. 2). CSF tau and A $\beta$  were each significantly correlated with memory z-

242 scores in both sexes, regardless of genotype (Table 3). There were no significant sex by APOE  
243 genotype interactions for memory scores (Table 2).

244

### 245 *3.4. Diagnosis and APOE are associated with changes in memory, hippocampal volume, and* 246 *tau-pathology*

247 Two-way interactions between diagnosis and APOE genotype were detected for memory  
248 z-scores ( $p=0.006$ ), hippocampal volume (the two correction methods; both  $p$ 's $<0.001$ ), and CSF  
249 tau ( $p=0.014$ ) and ptau levels ( $p=0.029$ ) but not for executive function scores or CSF A $\beta$  levels.  
250 As expected, increasing severity of diagnosis decreases memory z-scores in carriers and non-  
251 carriers of APOE $\epsilon$ 4 alleles ( $p$ 's $<0.001$ ). However, carrying APOE $\epsilon$ 4 alleles decreased memory  
252 scores in the LMCI group ( $p<0.0001$ ), but not in the CN, EMCI, and probable AD groups (all  
253  $p$ 's $>0.2$ ), compared to non-carriers.

254 For both methods of hippocampal volume calculation, we found that, irrespective of sex,  
255 carriers of APOE $\epsilon$ 4 alleles had a smaller volume compared to non-carriers in LMCI and  
256 probable AD individuals (regression method:  $p<0.0001$  and  $p=0.0004$ , respectively; ratio  
257 method:  $p=0.0001$  and  $p=0.001$ , respectively). There were no significant differences in  
258 hippocampal volume between carriers and non-carriers of APOE $\epsilon$ 4 alleles in the EMCI and CN  
259 groups ( $p$ 's $>0.5$ ). In non-carriers, severity of diagnosis was associated with a smaller  
260 hippocampal volume, regardless of method of correction (AD $<$ LMCI $<$ EMCI $<$ CN;  $p$ 's $<0.01$ ).  
261 In carriers of APOE $\epsilon$ 4 alleles, EMCI diagnosis did not significantly affect hippocampal volume  
262 compared to CN individuals with both methods of correction ( $p$ 's $>0.7$ ) while there was a  
263 reduction in hippocampal volume in probable AD and LMCI (AD $<$ LMCI $<$ CN;  $p$ 's $<0.0001$ ).

264 There were no significant sex by diagnosis or sex by APOE genotype interactions for  
265 hippocampal volume (Table 2).

266 CSF tau and ptau levels increased with the severity of diagnosis but this was affected by  
267 APOE genotype ( $p=0.014$  and  $p=0.029$ , respectively). Carrying APOE $\epsilon$ 4 alleles resulted in  
268 higher levels of CSF tau and ptau in EMCI and LMCI (all  $p$ 's $<0.0001$ ), but not in CN or  
269 probable AD, individuals ( $p$ 's $>0.17$ ). Regardless of sex, the difference in CSF tau and ptau levels  
270 between non-carriers and carriers of APOE $\epsilon$ 4 alleles was reduced in individuals with probable  
271 AD compared to EMCI and LMCI diagnoses.

272

### 273 *3.5. Sex is associated with hippocampal volume*

274 Males had a larger hippocampus volume by the regression method, but a smaller  
275 proportion of the brain was devoted to hippocampus (ratio method) when compared to females  
276 (main effect of sex,  $p=0.005$  and  $p<0.0001$ , respectively; Table 2). Sex differences in  
277 hippocampal volume were observed regardless of diagnosis or APOE genotype.

278

### 279 *3.6. Diagnosis is associated with A $\beta$ and executive function*

280 Irrespective of sex and APOE genotype, increasing severity of diagnosis was associated  
281 with lower CSF A $\beta$  levels in LMCI and probable AD compared to CN individuals ( $p<0.0001$ ).  
282 A $\beta$  levels were similar in CN and EMCI individuals ( $p=0.1$ ). Increasing severity of diagnosis  
283 was associated with lower executive function z-scores ( $p<0.0001$ ), irrespective of sex and APOE  
284 genotype.

285

## 286 4. Discussion

287 In the present study, we found that APOE genotype affects AD neuropathology  
288 differently in males and females. CSF tau pathology was disproportionately elevated in female  
289 carriers of APOE $\epsilon$ 4 alleles, whereas CSF A $\beta$  was disproportionately reduced in male carriers of  
290 APOE $\epsilon$ 4 alleles. These findings suggest that APOE genotype leads to greater AD  
291 neuropathology in both sexes that depends on the pathology biomarker, with females more likely  
292 to show higher CSF tau levels and males to present with lower CSF A $\beta$  levels (suggesting a  
293 higher A $\beta$  deposition). Females displayed higher memory scores than males in CN, EMCI, and  
294 LMCI groups but not in probable AD, which may contribute to delayed diagnosis in females  
295 (Sundermann et al., 2017) and/or to the more severe decline in memory across diagnosis in  
296 females compared to males (Buckley et al., 2018; Irvine et al., 2012; Wang et al., 2019).  
297 Interestingly, depending on the correction method, females had either smaller or larger  
298 hippocampus volume compared to males, regardless of APOE genotype or diagnosis. As  
299 expected, increasing severity of diagnosis reduced executive function and CSF A $\beta$ , irrespective  
300 of sex and APOE genotype, and APOE genotype affected memory, hippocampal volume, and  
301 tau-pathology depending on diagnosis. Previous work has demonstrated sex differences in rates  
302 of AD and symptoms of AD (reviewed in Ferretti et al., 2018; Nebel et al., 2018). Our current  
303 study suggests that AD biomarkers (CSF tau and A $\beta$ ) are expressed differently between the sexes  
304 with APOE genotype, suggesting different AD pathology pathways between females and males  
305 carriers of APOE $\epsilon$ 4 alleles. These data may provide clues to better understand the sex differences  
306 in AD lifetime risk and progression.

307

308 *4.1 APOE genotype affects tau and A $\beta$  pathology differently between the sexes*

309 We found that levels of tau and p-tau were disproportionately elevated with APOE $\epsilon$ 4  
310 allele expression in females compared to males. Previous ADNI studies have found a significant  
311 interaction between sex and APOE genotype on levels of CSF tau in CN (Damoiseaux et al.,  
312 2012; but see Sampedro et al., 2015; Buckley et al., 2019a; Altmann et al., 2014) and aMCI  
313 participants (Altmann et al., 2014). A recent meta-analysis found a stronger association between  
314 APOE $\epsilon$ 4 and tau levels in CN females compared to males using ADNI and other datasets  
315 (Hohman et al., 2018). Our data extends these data by adding that the interaction between sex  
316 and APOE genotype on CSF tau and ptau is seen regardless of diagnosis (in CN, EMCI, LMCI  
317 and AD individuals). A recent study using a different cohort found that CSF ptau levels were not  
318 significantly higher in female APOE $\epsilon$ 4 carriers diagnosed with probable AD but a sex difference  
319 was found in earlier stages of the disease, i.e., subjective cognitive decline and MCI (Babapour  
320 Mofrad et al., 2020). Previous studies indicate that females with at least one APOE $\epsilon$ 4 allele are at  
321 a greater risk for developing AD earlier than are males with this allele (Altmann et al., 2014; Neu  
322 et al., 2017), and sex differences in tau and p-tau may be one underlying mechanism by which  
323 this occurs but further replication with additional and larger populations are needed.

324 In contrast to tau pathology, CSF A $\beta$  levels were disproportionately reduced in male  
325 APOE $\epsilon$ 4 carriers compared to females, suggesting a greater A $\beta$  deposition in male carriers of  
326 APOE $\epsilon$ 4 alleles, regardless of diagnosis. To date, studies have not been consistent regarding sex  
327 differences in CSF A $\beta$  levels or A $\beta$  deposition based on APOE genotype. For example,  
328 somewhat consistent with our findings some studies have found that male APOE $\epsilon$ 4 carriers have  
329 lower CSF A $\beta$  levels in CN individuals (but not in aMCI individuals; Altman et al., 2014), and  
330 that males, regardless of APOE status, have higher A $\beta$  deposition (using PET) than females in  
331 certain brain regions (i.e., cingulate cortex; Cavado et al., 2018). However, other studies in

332 cognitively healthy individuals find no sex differences in A $\beta$  deposition (Jack et al., 2015) or that  
333 females have higher levels of A $\beta$  deposition (Sundermann et al., 2018), regardless of APOE  
334 genotype. Differences between studies may be due to differences between CSF and PET A $\beta$   
335 levels and types of analysis. Levels of CSF tau are hypothesized to increase after CSF A $\beta$   
336 declines and A $\beta$  aggregates and deposits in the brain (Blennow et al., 2015). The association  
337 between tau and A $\beta$  is also well characterized, i.e., increasing tau PET levels are associated with  
338 increasing A $\beta$  PET deposition (e.g., Maass et al., 2017). Based on this, we would have expected  
339 lower CSF A $\beta$  to be associated with higher CSF tau and ptau, which is precisely what we found  
340 in females, regardless of APOE genotype, but only in male non-carriers of APOE $\epsilon$ 4 alleles.  
341 Previous work is consistent with this finding, as higher levels of tau PET were more strongly  
342 associated with higher A $\beta$  burden in the entorhinal cortex in females compared to males  
343 (Buckley et al., 2019b). Taken together, this suggests that the weaker relationship between tau  
344 and A $\beta$  in males is due to APOE genotype and the stronger relationship in females between tau  
345 and A $\beta$  is seen regardless of APOE genotype and these sex differences may drive inconsistencies  
346 between studies. However, CSF tau and A $\beta$  were similarly correlated with memory scores in  
347 both sexes and APOE genotype. It is possible that depending on APOE genotype, the  
348 neurodegeneration pathway (tau or A $\beta$ ) or timeline of pathology is different between the sexes,  
349 but whichever pathway is present, it is correlated with lower memory scores.

350

#### 351 *4.2 AD diagnosis decreased memory scores to a greater extent in females*

352 As expected, we found that the presence of APOE $\epsilon$ 4 alleles and probable AD diagnosis  
353 were associated with reduced memory and executive function scores consistent with past  
354 literature (Buckner, 2004; Ewers et al., 2012; Petersen et al., 2000). However, memory scores in

355 females were more affected with diagnosis such that the female memory advantage was reduced  
356 with probable AD, and this is in line with longitudinal analyses showing females decline faster  
357 (although this may depend on APOE genotype and A $\beta$  burden; Holland et al., 2013; Buckley et  
358 al., 2018). Executive function on the other hand was similarly reduced in females and males with  
359 diagnosis. Previous studies found that females have better verbal memory compared to males  
360 across diagnoses (CN, Jack et al., 2015; aMCI and probable AD, Sundermann et al., 2018, 2016).  
361 Here, we used the ADNI memory score developed by Crane et al. (2012) to detect abnormal  
362 memory including language, attention, and logical memory. It is possible that verbal memory  
363 may be driving the sex difference favouring females in the present study, however individual  
364 cognitive scores will need to be analysed to confirm this. In contrast, Buckley et al. (2018) found  
365 no sex differences using a composite cognitive score that includes memory and executive  
366 function (Preclinical Alzheimer's Cognitive Composite score with semantic processing, PACC5)  
367 using ADNI and two other cohorts. Altogether, we found that in females CSF tau pathology was  
368 increased with APOE genotype and that in CN, EMCI and LMCI females (regardless of APOE  
369 genotype) memory and executive function scores were higher compared to males suggesting  
370 females have a reserve against brain pathology that delays either the onset of cognitive decline or  
371 diagnosis (Sundermann et al., 2017). Females may also use different coping strategies which  
372 delay manifestation of clinical symptoms, and in turn females may be less likely to be diagnosed  
373 with MCI or AD, as is the case with other conditions such as cardiovascular disease (Norris et  
374 al., 2020). Another study found that demographic differences (education and socioeconomic  
375 status) can affect sex differences in cognition. Males score better in verbal learning in  
376 impoverished and poor health cohorts and this is also associated with better education in males.  
377 In contrast, females score better when they have better education even when using education as a



378 covariate (Hogervorst et al., 2012). These results suggest that more detailed neuropsychological  
379 analyses are important to consider, along with the use of composite or individual cognitive  
380 scores, and that education is a moderating variable in the effects of sex on neuropsychological  
381 measures of cognition. The use of education as a moderating variable to influence cognitive  
382 memory scores across diagnosis and genotype will be an important factor in future studies.  
383 However, once cognitive decline begins, sex differences in memory scores are reduced (current  
384 study) and females show higher rates of declines compared to males (Buckley et al., 2018;  
385 Holland et al., 2013; Hua et al., 2010) perhaps because the underlying tau pathology is elevated  
386 in females.

387 Females have a higher lifetime risk of AD than males and show greater cognitive decline  
388 with AD than males (reviewed by Ferretti et al., 2018; Nebel et al., 2018). The disproportionate  
389 effect in females compared to males of (1) APOE $\epsilon$ 4 genotype on tau-related pathology and (2)  
390 AD diagnosis on memory scores supports the idea that females have a higher burden of the  
391 disease, although not all studies agree (Jack et al., 2019; reviewed in Nebel et al., 2018).  
392 Intriguingly, males are more likely to be diagnosed with aMCI compared to females (Jack et al.,  
393 2019), whereas females progress faster from aMCI to AD (Lin et al., 2015). These findings are  
394 similar to those in the current study as we found more males than females diagnosed with LMCI  
395 but no sex difference in frequency in probable AD. Altogether, our study and previous research  
396 suggests that AD females “catch up” to males and sex differences in tau-related pathology found  
397 in the current study may be the underlying mechanism for this accelerated transition.

398

399 *4.3 Sex differences in hippocampal volume depended on correction method*

400 We found that the presence of APOE $\epsilon$ 4 alleles and probable AD diagnosis were  
401 associated with reduced corrected hippocampal volume (both methods of correction) consistent  
402 with previous literature (Buckner, 2004; Ewers et al., 2012; Jack et al., 2000; Li et al., 2016;  
403 Petersen et al., 2000). Curiously, depending on the correction method, females had larger or  
404 smaller hippocampal volume compared to males. Females had smaller corrected hippocampal  
405 volume using the residuals of the linear regression between hippocampal volume and total  
406 intracranial volume (regression method) but larger ratio of hippocampal/intracranial volume  
407 compared to males. Similar findings have been shown before as sex differences depend on  
408 whether hippocampal volume is corrected for by intracranial volume or total brain volume, and  
409 the method of correction (Tan et al., 2016). In their meta-analysis, Tan et al. (2016) conclude  
410 that sex differences in hippocampal volume are modest and highly depends on whether or not a  
411 correction was applied and the method of correction which is supported by our findings. These  
412 results have important implications for understanding sex differences in diseases that influence  
413 the integrity of the hippocampus as they lead to very different conclusions regarding  
414 hippocampal plasticity.

415

#### 416 *4.4 Limitations*

417 The ADNI data are not representative of the population as it is mostly composed of white  
418 and highly educated individuals. As ethnicity (Mayeda et al., 2016; Steenland et al., 2016) and  
419 education (Sharp and Gatz, 2011) can affect incidence, prevalence and age of AD onset, our  
420 conclusions may not apply to more ethnically and socially diverse populations. Although we  
421 controlled for education levels, education in itself is an important contributing factor and may  
422 impact sex differences in cognitive decline (Hogervorst et al., 2012). It is also possible that the

423 protective effects of education vary with race/ethnicity (Avila et al., 2021), therefore future  
424 studies in more representative populations are needed. In addition, other pathologies in these  
425 participants, such as cancer, cardiovascular disease, diabetes, or smoking status may have  
426 influenced our measures of AD pathology, cognition, and hippocampal volume (Durazzo et al.,  
427 2014; Mezencev and Chernoff, 2020; Santiago and Potashkin, 2021). In this cohort, we did not  
428 detect significant interactions between sex, APOE genotype, and diagnosis for any of the  
429 endpoints analysed. Future research with large cohorts is required to further test how sex, APOE  
430 genotype, and diagnosis interact together as well as how other life history characteristics such as  
431 parity may play a role.

432

## 433 **6. Conclusion**

434 Levels of CSF tau and p-tau were disproportionately affected by APOE genotype in  
435 females compared to males, however males had a higher reduction in CSF A $\beta$  levels with APOE  
436 genotype compared to females. Our results support the idea that there are sex differences in the  
437 manifestation and pathology of AD with APOE genotype. Interestingly, although in this cohort  
438 female APOE $\epsilon$ 4 carriers had elevated tau pathology, females (regardless of APOE genotype) had  
439 higher memory scores compared to males in CN and aMCI groups. Therefore, it is possible that  
440 females may have a reserve that protects the brain from damage to delay cognitive decline or  
441 delay diagnosis but as the disease progresses the advantage in memory is reduced and females  
442 show a faster trajectory of cognitive decline.

443

## 444 **Acknowledgments**

445 Data collection and sharing for this project was funded by the Alzheimer's Disease  
446 Neuroimaging Initiative (ADNI) (National Institutes of Health Grant U01 AG024904) and DOD  
447 ADNI (Department of Defense award number W81XWH-12-2-0012). ADNI is funded by the  
448 National Institute on Aging, the National Institute of Biomedical Imaging and Bioengineering,  
449 and through generous contributions from the following: AbbVie, Alzheimer's Association;  
450 Alzheimer's Drug Discovery Foundation; Araclon Biotech; BioClinica, Inc.; Biogen; Bristol-  
451 Myers Squibb Company; CereSpir, Inc.; Cogstate; Eisai Inc.; Elan Pharmaceuticals, Inc.; Eli  
452 Lilly and Company; EuroImmun; F. Hoffmann-La Roche Ltd and its affiliated company  
453 Genentech, Inc.; Fujirebio; GE Healthcare; IXICO Ltd.; Janssen Alzheimer Immunotherapy  
454 Research & Development, LLC.; Johnson & Johnson Pharmaceutical Research & Development  
455 LLC.; Lumosity; Lundbeck; Merck & Co., Inc.; Meso Scale Diagnostics, LLC.; NeuroRx  
456 Research; Neurotrack Technologies; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Piramal  
457 Imaging; Servier; Takeda Pharmaceutical Company; and Transition Therapeutics. The Canadian  
458 Institutes of Health Research is providing funds to support ADNI clinical sites in Canada. Private  
459 sector contributions are facilitated by the Foundation for the National Institutes of Health  
460 ([www.fnih.org](http://www.fnih.org)). The grantee organization is the Northern California Institute for Research and  
461 Education, and the study is coordinated by the Alzheimer's Therapeutic Research Institute at the  
462 University of Southern California. ADNI data are disseminated by the Laboratory for Neuro  
463 Imaging at the University of Southern California. Funding for this study was provided by a  
464 Canadian Institutes of Health Research (CHIR) grant to LAMG (PJT-148662). PDG is funded by  
465 the Alzheimer's Association of the USA and Brain Canada with the financial support of Health  
466 Canada through the Brain Canada Research Fund (AARF-17-529705). The views expressed

467 herein do not necessarily represent the views of the Minister of Health or the Government of  
468 Canada.

469

## 470 **References**

- 471 Altmann, A., Tian, L., Henderson, V.W., Greicius, M.D., 2014. Sex modifies the APOE-related risk of  
472 developing Alzheimer disease. *Annals of Neurology* 75, 563–573.  
473 <https://doi.org/10.1002/ana.24135>
- 474 Alzheimer's Association, 2017. 2017 Alzheimer's disease facts and figures. *Alzheimer's & Dementia* 13,  
475 325–373. <https://doi.org/10.1016/j.jalz.2017.02.001>
- 476 Ardekani, B.A., Convit, A., Bachman, A.H., 2016. Analysis of the MIRIAD Data Shows Sex Differences  
477 in Hippocampal Atrophy Progression. *J. Alzheimers Dis.* 50, 847–857.  
478 <https://doi.org/10.3233/JAD-150780>
- 479 Asperholm, M., Högman, N., Rafi, J., Herlitz, A., 2019. What did you do yesterday? A meta-analysis of  
480 sex differences in episodic memory. *Psychol Bull* 145, 785–821.  
481 <https://doi.org/10.1037/bul0000197>
- 482 Avila, J.F., Rentería, M.A., Jones, R.N., Vonk, J.M.J., Turney, I., Sol, K., Seblova, D., Arias, F., Hill-  
483 Jarrett, T., Levy, S.-A., Meyer, O., Racine, A.M., Tom, S.E., Melrose, R.J., Deters, K., Medina,  
484 L.D., Carrión, C.I., Díaz-Santos, M., Byrd, D.R., Chesebro, A., Colon, J., Igwe, K.C., Maas, B.,  
485 Brickman, A.M., Schupf, N., Mayeux, R., Manly, J.J., 2021. Education differentially contributes  
486 to cognitive reserve across racial/ethnic groups. *Alzheimer's & Dementia* 17, 70–80.  
487 <https://doi.org/10.1002/alz.12176>
- 488 Babapour Mofrad, R., Tijms, B.M., Scheltens, P., Barkhof, F., van der Flier, W.M., Sikkes, S.A.M.,  
489 Teunissen, C.E., 2020. Sex differences in CSF biomarkers vary by Alzheimer disease stage and  
490 APOE  $\epsilon$ 4 genotype. *Neurology* 95, e2378–e2388.  
491 <https://doi.org/10.1212/WNL.0000000000010629>
- 492 Benjamini, Y., Hochberg, Y., 1995. Controlling the False Discovery Rate: A Practical and Powerful  
493 Approach to Multiple Testing. *Journal of the Royal Statistical Society. Series B (Methodological)*  
494 57, 289–300.
- 495 Blennow, K., Dubois, B., Fagan, A.M., Lewczuk, P., de Leon, M.J., Hampel, H., 2015. Clinical utility of  
496 cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease. *Alzheimer's &*  
497 *Dementia* 11, 58–69. <https://doi.org/10.1016/j.jalz.2014.02.004>
- 498 Buckley, R.F., Mormino, E.C., Amariglio, R.E., Properzi, M.J., Rabin, J.S., Lim, Y.Y., Papp, K.V.,  
499 Jacobs, H.I.L., Burnham, S., Hanseeuw, B.J., Doré, V., Dobson, A., Masters, C.L., Waller, M.,  
500 Rowe, C.C., Maruff, P., Donohue, M.C., Rentz, D.M., Kirn, D., Hedden, T., Chhatwal, J.,  
501 Schultz, A.P., Johnson, K.A., Villemagne, V.L., Sperling, R.A., 2018. Sex, amyloid, and APOE  
502  $\epsilon$ 4 and risk of cognitive decline in preclinical Alzheimer's disease: Findings from three well-  
503 characterized cohorts. *Alzheimer's & Dementia* 14, 1193–1203.  
504 <https://doi.org/10.1016/j.jalz.2018.04.010>
- 505 Buckley, R.F., Mormino, E.C., Chhatwal, J., Schultz, A.P., Rabin, J.S., Rentz, D.M., Acar, D., Properzi,  
506 M.J., Dumurgier, J., Jacobs, H., Gomez-Isla, T., Johnson, K.A., Sperling, R.A., Hanseeuw, B.J.,  
507 2019a. Associations between baseline amyloid, sex, and APOE on subsequent tau accumulation  
508 in cerebrospinal fluid. *Neurobiology of Aging* 78, 178–185.  
509 <https://doi.org/10.1016/j.neurobiolaging.2019.02.019>
- 510 Buckley, R.F., Mormino, E.C., Rabin, J.S., Hohman, T.J., Landau, S., Hanseeuw, B.J., Jacobs, H.I.L.,  
511 Papp, K.V., Amariglio, R.E., Properzi, M.J., Schultz, A.P., Kirn, D., Scott, M.R., Hedden, T.,  
512 Farrell, M., Price, J., Chhatwal, J., Rentz, D.M., Villemagne, V.L., Johnson, K.A., Sperling, R.A.,

- 2019b. Sex Differences in the Association of Global Amyloid and Regional Tau Deposition Measured by Positron Emission Tomography in Clinically Normal Older Adults. *JAMA Neurol* 76, 542–551. <https://doi.org/10.1001/jamaneurol.2018.4693>
- Buckner, R.L., 2004. Memory and Executive Function in Aging and AD: Multiple Factors that Cause Decline and Reserve Factors that Compensate. *Neuron* 44, 195–208. <https://doi.org/10.1016/j.neuron.2004.09.006>
- Cavedo, E., Chiesa, P.A., Houot, M., Ferretti, M.T., Grothe, M.J., Teipel, S.J., Lista, S., Habert, M.-O., Potier, M.-C., Dubois, B., Hampel, H., Bakardjian, H., Benali, H., Bertin, H., Bonheur, J., Boukadida, L., Boukerrou, N., Cavedo, E., Chiesa, P., Colliot, O., Dubois, B., Dubois, M., Epelbaum, S., Gagliardi, G., Genthon, R., Habert, M.-O., Hampel, H., Houot, M., Kas, A., Lamari, F., Levy, M., Lista, S., Metzinger, C., Mochel, F., Nyasse, F., Poisson, C., Potier, M.-C., Revillon, M., Santos, A., Andrade, K.S., Sole, M., Surtee, M., de Schotten, M.T., Vergallo, A., Younsi, N., Aguilar, L.F., Babiloni, C., Baldacci, F., Benda, N., Black, K.L., Bokde, A.L.W., Bonuccelli, U., Broich, K., Bun, R.S., Cacciola, F., Castrillo, J., Cavedo, E., Ceravolo, R., Chiesa, P.A., Colliot, O., Coman, C.-M., Corvol, J.-C., Cuello, A.C., Cummings, J.L., Depypere, H., Dubois, B., Duggento, A., Durrleman, S., Escott-Price, V., Federoff, H., Ferretti, M.T., Fiandaca, M., Frank, R.A., Garaci, F., Genthon, R., George, N., Giorgi, F.S., Graziani, M., Haberkamp, M., Habert, M.-O., Hampel, H., Herholz, K., Karran, E., Kim, S.H., Koronyo, Y., Koronyo-Hamaoui, M., Lamari, F., Langevin, T., Lehéricy, S., Lista, S., Lorenceau, J., Mapstone, M., Neri, C., Nisticò, R., Nyasse-Messene, F., O'bryant, S.E., Perry, G., Ritchie, C., Rojkova, K., Rossi, S., Saidi, A., Santarnecchi, E., Schneider, L.S., Sporns, O., Toschi, N., Verdooner, S.R., Vergallo, A., Villain, N., Welikovitch, L.A., Woodcock, J., Younesi, E., 2018. Sex differences in functional and molecular neuroimaging biomarkers of Alzheimer's disease in cognitively normal older adults with subjective memory complaints. *Alzheimer's & Dementia* 14, 1204–1215. <https://doi.org/10.1016/j.jalz.2018.05.014>
- Crane, P.K., Carle, A., Gibbons, L.E., Insel, P., Mackin, R.S., Gross, A., Jones, R.N., Mukherjee, S., Curtis, S.M., Harvey, D., Weiner, M., Mungas, D., Alzheimer's Disease Neuroimaging Initiative, 2012. Development and assessment of a composite score for memory in the Alzheimer's Disease Neuroimaging Initiative (ADNI). *Brain Imaging Behav* 6, 502–516. <https://doi.org/10.1007/s11682-012-9186-z>
- Damoiseaux, J.S., Seeley, W.W., Zhou, J., Shirer, W.R., Coppola, G., Karydas, A., Rosen, H.J., Miller, B.L., Kramer, J.H., Greicius, M.D., Alzheimer's Disease Neuroimaging Initiative, 2012. Gender modulates the APOE  $\epsilon$ 4 effect in healthy older adults: convergent evidence from functional brain connectivity and spinal fluid tau levels. *J. Neurosci.* 32, 8254–8262. <https://doi.org/10.1523/JNEUROSCI.0305-12.2012>
- Durazzo, T.C., Mattsson, N., Weiner, M.W., 2014. Smoking and increased Alzheimer's disease risk: A review of potential mechanisms. *Alzheimers Dement* 10, S122–S145. <https://doi.org/10.1016/j.jalz.2014.04.009>
- Ewers, M., Walsh, C., Trojanowski, J.Q., Shaw, L.M., Petersen, R.C., Jack, C.R., Feldman, H.H., Bokde, A.L.W., Alexander, G.E., Scheltens, P., Vellas, B., Dubois, B., Weiner, M., Hampel, H., 2012. Prediction of conversion from mild cognitive impairment to Alzheimer's disease dementia based upon biomarkers and neuropsychological test performance. *Neurobiology of Aging* 33, 1203–1214.e2. <https://doi.org/10.1016/j.neurobiolaging.2010.10.019>
- Ferretti, M.T., Iulita, M.F., Cavedo, E., Chiesa, P.A., Schumacher Dimech, A., Santucci Chadha, A., Baracchi, F., Girouard, H., Misoch, S., Giacobini, E., Depypere, H., Hampel, H., 2018. Sex differences in Alzheimer disease — the gateway to precision medicine. *Nature Reviews Neurology* 14, 457–469. <https://doi.org/10.1038/s41582-018-0032-9>
- Gaillard, A., Fehring, D.J., Rossell, S.L., 2020. A systematic review and meta-analysis of behavioural sex differences in executive control. *European Journal of Neuroscience*. <https://doi.org/10.1111/ejn.14946>

- 563 Gibbons, L.E., Carle, A.C., Mackin, R.S., Harvey, D., Mukherjee, S., Insel, P., Curtis, S.M., Mungas, D.,  
564 Crane, P.K., Alzheimer's Disease Neuroimaging Initiative, 2012. A composite score for  
565 executive functioning, validated in Alzheimer's Disease Neuroimaging Initiative (ADNI)  
566 participants with baseline mild cognitive impairment. *Brain Imaging Behav* 6, 517–527.  
567 <https://doi.org/10.1007/s11682-012-9176-1>
- 568 Hogervorst, E., Rahardjo, T.B., Jolles, J., Brayne, C., Henderson, V.W., 2012. Gender differences in  
569 verbal learning in older participants. *Aging Health* 8, 493–507. <https://doi.org/10.2217/ahe.12.56>
- 570 Hohman, T.J., Dumitrescu, L., Barnes, L.L., Thambisetty, M., Beecham, G., Kunkle, B., Gifford, K.A.,  
571 Bush, W.S., Chibnik, L.B., Mukherjee, S., Jager, P.L.D., Kukull, W., Crane, P.K., Resnick, S.M.,  
572 Keene, C.D., Montine, T.J., Schellenberg, G.D., Haines, J.L., Zetterberg, H., Blennow, K.,  
573 Larson, E.B., Johnson, S.C., Albert, M., Bennett, D.A., Schneider, J.A., Jefferson, A.L., 2018.  
574 Sex-Specific Association of Apolipoprotein E With Cerebrospinal Fluid Levels of Tau. *JAMA*  
575 *Neurol* 75, 989–998. <https://doi.org/10.1001/jamaneurol.2018.0821>
- 576 Holland, D., Desikan, R.S., Dale, A.M., McEvoy, L.K., Alzheimer's Disease Neuroimaging Initiative,  
577 2013. Higher rates of decline for women and apolipoprotein E epsilon4 carriers. *AJNR Am J*  
578 *Neuroradiol* 34, 2287–2293. <https://doi.org/10.3174/ajnr.A3601>
- 579 Hua, X., Hibar, D.P., Lee, S., Toga, A.W., Jack, C.R., Weiner, M.W., Thompson, P.M., 2010. Sex and  
580 age differences in atrophic rates: an ADNI study with n=1368 MRI scans. *Neurobiology of Aging*  
581 31, 1463–1480. <https://doi.org/10.1016/j.neurobiolaging.2010.04.033>
- 582 Irvine, K., Laws, K.R., Gale, T.M., Kondel, T.K., 2012. Greater cognitive deterioration in women than  
583 men with Alzheimer's disease: a meta analysis. *J Clin Exp Neuropsychol* 34, 989–998.  
584 <https://doi.org/10.1080/13803395.2012.712676>
- 585 Jack, C.R., Dickson, D.W., Parisi, J.E., Xu, Y.C., Cha, R.H., O'Brien, P.C., Edland, S.D., Smith, G.E.,  
586 Boeve, B.F., Tangalos, E.G., Kokmen, E., Petersen, R.C., 2002. Antemortem MRI Findings  
587 Correlate with Hippocampal Neuropathology in Typical Aging and Dementia. *Neurology* 58,  
588 750–757.
- 589 Jack, C.R., Knopman, D.S., Weigand, S.D., Wiste, H.J., Vemuri, P., Lowe, V., Kantarci, K., Gunter, J.L.,  
590 Senjem, M.L., Ivnik, R.J., Roberts, R.O., Rocca, W.A., Boeve, B.F., Petersen, R.C., 2012. An  
591 operational approach to National Institute on Aging–Alzheimer's Association criteria for  
592 preclinical Alzheimer disease. *Annals of Neurology* 71, 765–775.  
593 <https://doi.org/10.1002/ana.22628>
- 594 Jack, C.R., Petersen, R.C., Xu, Y., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Boeve, B.F., Tangalos, E.G.,  
595 Kokmen, E., 2000. Rates of hippocampal atrophy correlate with change in clinical status in aging  
596 and AD. *Neurology* 55, 484–489. <https://doi.org/10.1212/wnl.55.4.484>
- 597 Jack, C.R., Therneau, T.M., Weigand, S.D., Wiste, H.J., Knopman, D.S., Vemuri, P., Lowe, V.J., Mielke,  
598 M.M., Roberts, R.O., Machulda, M.M., Graff-Radford, J., Jones, D.T., Schwarz, C.G., Gunter,  
599 J.L., Senjem, M.L., Rocca, W.A., Petersen, R.C., 2019. Prevalence of Biologically vs Clinically  
600 Defined Alzheimer Spectrum Entities Using the National Institute on Aging–Alzheimer's  
601 Association Research Framework. *JAMA Neurol*. <https://doi.org/10.1001/jamaneurol.2019.1971>
- 602 Jack, C.R., Wiste, H.J., Weigand, S.D., Knopman, D.S., Vemuri, P., Mielke, M.M., Lowe, V., Senjem,  
603 M.L., Gunter, J.L., Machulda, M.M., Gregg, B.E., Pankratz, V.S., Rocca, W.A., Petersen, R.C.,  
604 2015. Age, Sex, and APOE ε4 Effects on Memory, Brain Structure, and β-Amyloid Across the  
605 Adult Life Span. *JAMA Neurol* 72, 511–519. <https://doi.org/10.1001/jamaneurol.2014.4821>
- 606 Kidron, D., Black, S.E., Stanehev, P., Buck, B., Szalai, J.P., Parker, J., Szekely, C., Bronskill, M.J., 1997.  
607 Quantitative MR volumetry in Alzheimer's disease: Topographic markers and the effects of sex  
608 and education. *Neurology* 49, 1504–1512. <https://doi.org/10.1212/WNL.49.6.1504>
- 609 Li, B., Shi, J., Gutman, B.A., Baxter, L.C., Thompson, P.M., Caselli, R.J., Wang, Y., 2016. Influence of  
610 APOE Genotype on Hippocampal Atrophy over Time - An N=1925 Surface-Based ADNI Study.  
611 *PLoS One* 11. <https://doi.org/10.1371/journal.pone.0152901>
- 612 Lin, K.A., Choudhury, K.R., Rathakrishnan, B.G., Marks, D.M., Petrella, J.R., Doraiswamy, P.M., 2015.  
613 Marked gender differences in progression of mild cognitive impairment over 8 years.

- 614 Alzheimer's & Dementia: Translational Research & Clinical Interventions 1, 103–110.  
615 <https://doi.org/10.1016/j.trci.2015.07.001>
- 616 Liu, M., Paranjpe, M.D., Zhou, X., Duy, P.Q., Goyal, M.S., Benzinger, T.L.S., Lu, J., Wang, R., Zhou,  
617 Y., 2019. Sex modulates the ApoE  $\epsilon$ 4 effect on brain tau deposition measured by 18F-AV-1451  
618 PET in individuals with mild cognitive impairment. *Theranostics* 9, 4959–4970.  
619 <https://doi.org/10.7150/thno.35366>
- 620 Lotze, M., Domin, M., Gerlach, F.H., Gaser, C., Lueders, E., Schmidt, C.O., Neumann, N., 2019. Novel  
621 findings from 2,838 Adult Brains on Sex Differences in Gray Matter Brain Volume. *Scientific*  
622 *Reports* 9, 1671. <https://doi.org/10.1038/s41598-018-38239-2>
- 623 Maass, A., Landau, S., Baker, S.L., Horng, A., Lockhart, S.N., La Joie, R., Rabinovici, G.D., Jagust,  
624 W.J., 2017. Comparison of multiple tau-PET measures as biomarkers in aging and Alzheimer's  
625 disease. *NeuroImage* 157, 448–463. <https://doi.org/10.1016/j.neuroimage.2017.05.058>
- 626 Mayeda, E.R., Glymour, M.M., Quesenberry, C.P., Whitmer, R.A., 2016. Inequalities in dementia  
627 incidence between six racial and ethnic groups over 14 years. *Alzheimer's & Dementia* 12, 216–  
628 224. <https://doi.org/10.1016/j.jalz.2015.12.007>
- 629 Mezencev, R., Chernoff, Y.O., 2020. Risk of Alzheimer's Disease in Cancer Patients: Analysis of  
630 Mortality Data from the US SEER Population-Based Registries. *Cancers (Basel)* 12.  
631 <https://doi.org/10.3390/cancers12040796>
- 632 Mormino, E.C., Betensky, R.A., Hedden, T., Schultz, A.P., Amariglio, R.E., Rentz, D.M., Johnson, K.A.,  
633 Sperling, R.A., 2014. Synergistic Effect of  $\beta$ -Amyloid and Neurodegeneration on Cognitive  
634 Decline in Clinically Normal Individuals. *JAMA Neurol* 71, 1379–1385.  
635 <https://doi.org/10.1001/jamaneurol.2014.2031>
- 636 Nebel, R.A., Aggarwal, N.T., Barnes, L.L., Gallagher, A., Goldstein, J.M., Kantarci, K., Mallampalli,  
637 M.P., Mormino, E.C., Scott, L., Yu, W.H., Maki, P.M., Mielke, M.M., 2018. Understanding the  
638 impact of sex and gender in Alzheimer's disease: A call to action. *Alzheimer's & Dementia* 14,  
639 1171–1183. <https://doi.org/10.1016/j.jalz.2018.04.008>
- 640 Neu, S.C., Pa, J., Kukull, W., Beekly, D., Kuzma, A., Gangadharan, P., Wang, L.-S., Romero, K.,  
641 Arneric, S.P., Redolfi, A., Orlandi, D., Frisoni, G.B., Au, R., Devine, S., Auerbach, S., Espinosa,  
642 A., Boada, M., Ruiz, A., Johnson, S.C., Kosciak, R., Wang, J.-J., Hsu, W.-C., Chen, Y.-L., Toga,  
643 A.W., 2017. Apolipoprotein E Genotype and Sex Risk Factors for Alzheimer Disease: A Meta-  
644 analysis. *JAMA Neurol*. <https://doi.org/10.1001/jamaneurol.2017.2188>
- 645 Norris, C.M., Yip, C.Y.Y., Nerenberg, K.A., Clavel, M.-A., Pacheco, C., Foulds, H.J.A., Hardy, M.,  
646 Gonsalves, C.A., Jaffer, S., Parry, M., Colella, T.J.F., Dhukai, A., Grewal, J., Price, J.A.D.,  
647 Levinsson, A.L.E., Hart, D., Harvey, P.J., Van Spall, H.G.C., Sarfi, H., Sedlak, T.L., Ahmed,  
648 S.B., Baer, C., Coutinho, T., Edwards, J.D., Green, C.R., Kirkham, A.A., Srivivaratharajah, K.,  
649 Dumanski, S., Keeping-Burke, L., Lappa, N., Reid, R.D., Robert, H., Smith, G., Martin-Rhee, M.,  
650 Mulvagh, S.L., 2020. State of the Science in Women's Cardiovascular Disease: A Canadian  
651 Perspective on the Influence of Sex and Gender. *J Am Heart Assoc* 9, e015634.  
652 <https://doi.org/10.1161/JAHA.119.015634>
- 653 Petersen, R.C., Aisen, P.S., Beckett, L.A., Donohue, M.C., Gamst, A.C., Harvey, D.J., Jack, C.R., Jagust,  
654 W.J., Shaw, L.M., Toga, A.W., Trojanowski, J.Q., Weiner, M.W., 2010. Alzheimer's Disease  
655 Neuroimaging Initiative (ADNI). *Neurology* 74, 201–209.  
656 <https://doi.org/10.1212/WNL.0b013e3181cb3e25>
- 657 Petersen, R.C., Jack, C.R., Xu, Y.C., Waring, S.C., O'Brien, P.C., Smith, G.E., Ivnik, R.J., Tangalos,  
658 E.G., Boeve, B.F., Kokmen, E., 2000. Memory and MRI-based hippocampal volumes in aging  
659 and AD. *Neurology* 54, 581–587. <https://doi.org/10.1212/wnl.54.3.581>
- 660 R Core Team, 2018. A language and environment for statistical computing. R Foundation for Statistical  
661 Computing, Vienna, Austria. URL <https://www.R-project.org/>.
- 662 Riedel, B.C., Thompson, P.M., Brinton, R.D., 2016. Age, APOE and sex: Triad of risk of Alzheimer's  
663 disease. *The Journal of Steroid Biochemistry and Molecular Biology* 160, 134–147.  
664 <https://doi.org/10.1016/j.jsbmb.2016.03.012>



- 665 Sampedro, F., Vilaplana, E., de Leon, M.J., Alcolea, D., Pegueroles, J., Montal, V., Carmona-Iragui, M.,  
666 Sala, I., Sánchez-Saudinos, M.-B., Antón-Aguirre, S., Morenas-Rodríguez, E., Camacho, V.,  
667 Falcón, C., Pavía, J., Ros, D., Clarimón, J., Blesa, R., Lleó, A., Fortea, J., Alzheimer's Disease  
668 Neuroimaging Initiative, 2015. APOE-by-sex interactions on brain structure and metabolism in  
669 healthy elderly controls. *Oncotarget* 6, 26663–26674. <https://doi.org/10.18632/oncotarget.5185>  
670 Santiago, J.A., Potashkin, J.A., 2021. The Impact of Disease Comorbidities in Alzheimer's Disease.  
671 *Front. Aging Neurosci.* 13. <https://doi.org/10.3389/fnagi.2021.631770>  
672 Sharp, E.S., Gatz, M., 2011. The Relationship between Education and Dementia An Updated Systematic  
673 Review. *Alzheimer Dis Assoc Disord* 25, 289–304.  
674 <https://doi.org/10.1097/WAD.0b013e318211c83c>  
675 Shaw, L.M., Vanderstichele, H., Knapik-Czajka, M., Clark, C.M., Aisen, P.S., Petersen, R.C., Blennow,  
676 K., Soares, H., Simon, A., Lewczuk, P., Dean, R., Siemers, E., Potter, W., Lee, V.M.-Y.,  
677 Trojanowski, J.Q., 2009. Cerebrospinal Fluid Biomarker Signature in Alzheimer's Disease  
678 Neuroimaging Initiative Subjects. *Ann Neurol* 65, 403–413. <https://doi.org/10.1002/ana.21610>  
679 Sohn, D., Shpanskaya, K., Lucas, J.E., Petrella, J.R., Saykin, A.J., Tanzi, R.E., Samatova, N.F.,  
680 Doraiswamy, P.M., 2018. Sex Differences in Cognitive Decline in Subjects with High Likelihood  
681 of Mild Cognitive Impairment due to Alzheimer's disease. *Scientific Reports* 8, 7490.  
682 <https://doi.org/10.1038/s41598-018-25377-w>  
683 Steenland, K., Goldstein, F.C., Levey, A., Wharton, W., 2016. A Meta-Analysis of Alzheimer's Disease  
684 Incidence and Prevalence Comparing African-Americans and Caucasians. *J. Alzheimers Dis.* 50,  
685 71–76. <https://doi.org/10.3233/JAD-150778>  
686 Sundermann, E.E., Biegon, A., Rubin, L.H., Lipton, R.B., Landau, S., Maki, P.M., Alzheimer's Disease  
687 Neuroimaging Initiative, 2017. Does the Female Advantage in Verbal Memory Contribute to  
688 Underestimating Alzheimer's Disease Pathology in Women versus Men? *J. Alzheimers Dis.* 56,  
689 947–957. <https://doi.org/10.3233/JAD-160716>  
690 Sundermann, E.E., Biegon, A., Rubin, L.H., Lipton, R.B., Mowrey, W., Landau, S., Maki, P.M., 2016.  
691 Better verbal memory in women than men in MCI despite similar levels of hippocampal atrophy.  
692 *Neurology* 86, 1368–1376. <https://doi.org/10.1212/WNL.0000000000002570>  
693 Sundermann, E.E., Tran, M., Maki, P.M., Bondi, M.W., 2018. Sex differences in the association between  
694 apolipoprotein E  $\epsilon$ 4 allele and Alzheimer's disease markers. *Alzheimer's & Dementia: Diagnosis,*  
695 *Assessment & Disease Monitoring* 10, 438–447. <https://doi.org/10.1016/j.dadm.2018.06.004>  
696 Tan, A., Ma, W., Vira, A., Marwha, D., Eliot, L., 2016. The human hippocampus is not sexually-  
697 dimorphic: Meta-analysis of structural MRI volumes. *NeuroImage* 124, 350–366.  
698 <https://doi.org/10.1016/j.neuroimage.2015.08.050>  
699 Wang, X., Zhou, W., Ye, T., Lin, X., Zhang, J., Initiative, for A.D.N., 2019. Sex Difference in the  
700 Association of APOE4 with Memory Decline in Mild Cognitive Impairment. *Journal of*  
701 *Alzheimer's Disease* 69, 1161–1169. <https://doi.org/10.3233/JAD-181234>  
702 Yagi, S., Galea, L.A.M., 2019. Sex differences in hippocampal cognition and neurogenesis.  
703 *Neuropsychopharmacology* 44, 200–213. <https://doi.org/10.1038/s41386-018-0208-4>  
704

705 **Figure captions**

706 **Figure 1.** A. Levels of CSF AD biomarkers tau (pg/ml; A), p-tau (pg/ml; B), and amyloid beta  
707 (pg/ml; C) in ADNI participants by sex and APOE genotype (absence or presence of APOE $\epsilon$ 4  
708 alleles).


709

710 **Figure 2.** Memory scores in ADNI participants by sex and diagnosis (CN, EMCI, LMCI, AD).  
711 CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive  
712 impairment; AD, Alzheimer's disease.


713

Figure 1

A



B



C





Figure 2



**Table 1.** Demographic and clinical information for all participants and subdivided by sex. We collapsed APOE genotype into two groups: (1) participants with no  $\epsilon 4$  risk alleles (-/-) and (2) participants carrying any  $\epsilon 4$  alleles (homozygous  $\epsilon 4/\epsilon 4$  and heterozygous  $\epsilon 4/-$ ). Biomarkers for AD are from cerebrospinal fluid. Volume of the hippocampus was corrected using a regression method or using a ratio with intracranial volume (see methods). CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer’s disease.

	Total No. 1,460	Sex		P-value	
		Female No. 630	Male No. 830		
<b>Age</b>					
Mean (SD)	74.13 ( $\pm 7.25$ )	73.15 ( $\pm 7.28$ )	74.87 ( $\pm 7.14$ )	< 0.0001	
<b>Education (years)</b>					
Mean (SD)	15.83 ( $\pm 2.88$ )	15.15 ( $\pm 2.79$ )	16.34 ( $\pm 2.85$ )	< 0.0001	
<b>Ethnicity</b>					
White	1,352 (92.60%)	573 (90.95%)	779 (93.86%)	0.043	
Not white	108 (7.40%)	57 (9.05%)	51 (6.14%)		
<b>Baseline diagnosis</b>					
CN	341 (23.4%)	168 (26.7%)	173 (20.8%)	0.013	
EMCI	257 (17.6%)	108 (17.1%)	149 (18.0%)		
LMCI	533 (36.5%)	205 (32.5%)	328 (39.5%)		
AD	329 (22.5%)	149 (23.7%)	180 (21.7%)		
<b>APOE<math>\epsilon 4</math> allele number</b>					
0	702 (48.08%)	300 (47.62%)	402 (48.43%)	0.87	
1 or 2	744 (50.96%)	322 (51.11%)	422 (50.84%)		
Missing	14 (0.96%)	8 (1.27%)	6 (0.72%)		
<b>Diagnosis by APOE genotype</b>					
CN	0	236 (69.21%)	111 (66.07%)	125 (72.25%)	0.34
	1 or 2	103 (30.21%)	55 (32.74%)	48 (27.75%)	
	Missing	2 (0.59%)	2 (1.19%)	0	
EMCI	0	128 (49.81%)	59 (54.63%)	69 (46.31%)	0.2
	1 or 2	123 (47.86%)	46 (42.59%)	77 (51.68%)	
	Missing	6 (2.33%)	3 (2.78%)	3 (2.01%)	
LMCI	0	233 (43.71%)	80 (39.02%)	153 (46.65%)	0.11
	1 or 2	298 (55.91%)	124 (60.49%)	174 (53.05%)	
	Missing	2 (0.38%)	1 (0.49%)	1 (0.30%)	
AD	0	105 (31.92%)	50 (33.56%)	55 (30.56%)	0.63
	1 or 2	220 (66.87%)	97 (65.10%)	123 (68.33%)	
	Missing	4 (1.22%)	2 (1.34%)	2 (1.11%)	
<b>Amyloid Beta</b>					
Mean (SD)	830.97 ( $\pm 358.04$ )	856.41 ( $\pm 346.87$ )	812.44 ( $\pm 365.16$ )	0.016	
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)		
<b>Tau</b>					
Mean (SD)	294.38 ( $\pm 137.27$ )	314.56 ( $\pm 152.70$ )	279.70 ( $\pm 122.91$ )	0.002	
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)		
<b>PTau</b>					
Mean (SD)	28.89 ( $\pm 15.31$ )	30.87 ( $\pm 16.95$ )	27.44 ( $\pm 13.83$ )	0.007	
Missing	513 (35.14%)	231 (36.67%)	282 (33.98%)		
<b>Volume of hippocampus (uncorrected, mm<sup>3</sup>)</b>					
Mean (SD)	6659.47 ( $\pm 1176.42$ )	6446.71 ( $\pm 1169.97$ )	6822.86 ( $\pm 1155.87$ )	< 0.0001	
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)		
<b>Volume of hippocampus (regression corrected)</b>					
Mean (SD)	6662.60 ( $\pm 1137.98$ )	6647.21 ( $\pm 1134.41$ )	6674.43 ( $\pm 1141.38$ )	0.83	
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)		
<b>Volume of hippocampus/intracranial volume</b>					
Mean (SD)	0.00436 ( $\pm 0.00080$ )	0.00454 ( $\pm 0.00082$ )	0.00423 ( $\pm 0.00076$ )	< 0.0001	
Missing	226 (15.48%)	94 (14.92%)	132 (15.90%)		
<b>Executive Function (ADNI_EF)</b>					
Mean (SD)	0.02 ( $\pm 0.96$ )	0.06 ( $\pm 0.97$ )	-0.00 ( $\pm 0.95$ )	0.20	
Missing	311 (21.30%)	145 (23.02%)	166 (20.00%)		
<b>Memory (ADNI_MEM)</b>					
Mean (SD)	0.10 ( $\pm 0.87$ )	0.21 ( $\pm 0.94$ )	0.02 ( $\pm 0.80$ )	0.0006	
Missing	310 (21.23%)	145 (23.02%)	165 (19.88%)		

P-values are from Wilcoxon rank sum tests for continuous variables and Fisher’s exact tests for categorical variables. Missing refers to number of individuals and the percent of the total cohort that had missing data for that variable

**Table 2.** Linear regression results for models with sex, baseline diagnosis (CN, cognitively normal; EMCI, early mild cognitive impairment; LMCI, late mild cognitive impairment; AD, Alzheimer's disease), and APOE4 genotype (non-carriers or carriers of APOEε4 alleles). P-values are for overall tests and are FDR-adjusted. The three-way interactions were not significant for any of the endpoints.

Predictors	CSF tau		CSF ptau		CSF amyloid beta		ADNI Memory z-scores		Hippocampus volume (regression method)		Hippocampus volume (ratio method)		ADNI executive function z-scores	
	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p	Estimates (CI)	adjusted p
(Intercept)	122.07 (21.39 – 222.75)		12.35 (1.07 – 23.63)		1345.53 (1090.27 – 1600.80)		1.23 (0.83 – 1.64)		11678.92 (11048.18 – 12309.67)		0.0078 (0.0074 – 0.0083)		1.16 (0.62 – 1.71)	
Age (years)	1.88 (0.79 – 2.97)	<b>0.05</b>	0.17 (0.05 – 0.29)		-3.44 (-6.21 – -0.67)		-0.009 (-0.01 – -0.01)	<b>0.0002</b>	-56.77 (-63.75 – -49.78)	<b>&lt;0.0001</b>	-0.000035 (-0.00004 – -0.00003)	<b>&lt;0.0001</b>	-0.02 (-0.02 – -0.01)	<b>&lt;0.0001</b>
Education (years)	-2.62 (-5.54 – 0.30)	<b>0.04</b>	-0.31 (-0.64 – 0.02)	<b>0.03</b>	-0.19 (-7.61 – 7.22)		0.04 (0.03 – 0.05)	<b>&lt;0.0001</b>	-5.20 (-22.72 – 12.33)		-0.000012 (-0.00003 – 0.0000001)		0.06 (0.05 – 0.08)	<b>&lt;0.0001</b>
Sex (ref = Female)	-12.49 (-36.01 – 11.04)		-0.90 (-3.53 – 1.74)		14.22 (-45.22 – 73.65)		-0.31 (-0.44 – -0.18)		160.82 (59.29 – 262.36)	<b>0.005</b>	-0.00021 (-0.00028 – -0.00014)	<b>&lt;0.0001</b>	-0.12 (-0.21 – -0.03)	<b>0.013</b>
APOE genotype 1/2 ε4 alleles (ref = 0 alleles)	68.10 (27.54 – 108.67)		7.89 (3.35 – 12.4)		-181.29 (-244.76 – -117.82)		0.003 (-0.13 – 0.14)		-168.09 (-383.49 – 47.30)		-0.000098 (-0.00025 – 0.00006)		-0.02 (-0.11 – 0.07)	
Diagnosis (ref = CN)							<b>&lt;0.0001</b>							<b>&lt;0.0001</b>
EMCI	7.3 (-23.08 – 37.68)		1.10 (-2.31 – 4.50)		-47.41 (-107.88 – 13.06)		-0.37 (-0.55 – -0.19)		-418.90 (-613.3 – -224.5)		-0.00027 (-0.00041 – -0.00013)		-0.36 (-0.51 – -0.22)	
LMCI	57.53 (28.00 – 87.06)		6.58 (3.27 – 9.89)		-199.57 (-256.43 – -142.71)		-0.99 (-1.13 – -0.84)		-870.94 (-1042.39 – -699.49)		-0.00062 (-0.00074 – -0.0005)		-0.74 (-0.85 – -0.63)	
AD	138.89 (103.05 – 174.73)		15.07 (11.05 – 19.08)		-302.02 (-364.13 – -239.92)		-1.87 (-2.04 – -1.70)		-1335.15 (-1557.41 – -1112.89)		-0.00089 (-0.0010 – -0.0007)		-1.54 (-1.67 – -1.41)	
Sex and APOE genotype interaction		<b>0.005</b>		<b>0.006</b>			<b>0.051</b>							
Male:1/2 alleles	-48.76 (-80.59 – -16.93)		-5.30 (-8.86 – -1.73)		-81.14 (-161.74 – -0.54)									
Sex and Diagnosis interaction							<b>0.048</b>							
Male:EMCI							-0.04 (-0.25 – 0.17)							
Male:LMCI							0.15 (-0.01 – 0.32)							
Male:AD							0.20 (0.01 – 0.38)							
APOE genotype and Diagnosis interaction		<b>0.014</b>		<b>0.029</b>			<b>0.006</b>		<b>0.0007</b>		<b>0.0006</b>			
1/2 alleles:EMCI	47.66 (-1.44 – 96.76)		4.57 (-0.94 – 10.07)				-0.15 (-0.36 – 0.06)		271.86 (-38.41 – 582.13)		0.00023 (0.000009 – 0.0005)			
1/2 alleles:LMCI	39.03 (-7.36 – 85.42)		4.20 (-1.00 – 9.39)				-0.28 (-0.45 – -0.11)		-282.50 (-553.38 – -11.63)		-0.00017 (-0.00036 – 0.00003)			
1/2 alleles:AD	-21.57 (-72.73 – 29.58)		-2.32 (-8.05 – 3.41)				-0.03 (-0.23 – 0.17)		-303.52 (-615.96 – 8.92)		-0.00021 (-0.0004 – 0.00009)			
Observations	947		947		947		1145		1224		1224		1144	
R <sup>2</sup> / R <sup>2</sup> adjusted	0.227 / 0.218		0.220 / 0.211		0.264 / 0.258		0.621 / 0.616		0.431 / 0.427		0.415 / 0.410		0.411 / 0.408	

**Table 3.** Correlations between CSF levels of tau and amyloid beta, CSF tau and memory scores, and CSF amyloid beta and memory scores, depending by sex and APOE genotype (non carriers versus carriers of  $\epsilon 4$  alleles)

<b>Variables</b>	<b>APOE genotype</b>	<b>Correlation in females</b>	<b>p-value</b>	<b>Correlation in males</b>	<b>p-value</b>
<b>CSF tau and A<math>\beta</math></b>					
	Non carriers	-0.195 (-0.330 to - 0.053)	<b>0.008</b>	-0.262 (-0.372 to -0.145)	<b>&lt; 0.0001</b>
	Carriers of APOE $\epsilon 4$ alleles	-0.219 (-0.343 to -0.088)	<b>0.001</b>	-0.046 (-0.160 to 0.070)	0.44
<b>CSF tau and memory z-scores</b>					
	Non carriers	-0.397 (-0.532 to -0.244)	<b>&lt; 0.0001</b>	-0.394 (-0.507 to -0.268)	<b>&lt; 0.0001</b>
	Carriers of APOE $\epsilon 4$ alleles	-0.242 (-0.387 to -0.086)	<b>0.003</b>	-0.232 (-0.355 to -0.100)	<b>0.0007</b>
<b>CSF A<math>\beta</math> and memory z-scores</b>					
	Non carriers	0.425 (0.275 to 0.555)	<b>&lt; 0.0001</b>	0.305 (0.172 to 0.428)	<b>&lt; 0.0001</b>
	Carriers of APOE $\epsilon 4$ alleles	0.407 (0.265 to 0.533)	<b>&lt; 0.0001</b>	0.413 (0.295 to 0.519)	<b>&lt; 0.0001</b>